To the editor,

I have read with interest the paper by Joseph et al on Duchenne muscular dystrophy, and bone health monitoring [1]. Their patient cohort has peculiar properties. The median loss of ambulation is 10.2 years of age. About half of them were non-ambulant at the time of the study. Sixty five percent of them were on steroids with entirely different regimens (daily deflazacort, pulsed deflazacort, daily prednisolone, pulsed prednisolone) for a median of 5.2 years at a median age of 5.5 years. In 10%, the treatment mode is unknown.
Source: Neuromuscular Disorders - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research